Alterity Therapeutics Limited Stock News

MELBOURNE, Australia, Jan. 5, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treat

Alterity Therapeutics Ltd - ADR (ATHE) shares closed today at 1.8% above its 52 week low of $0.81, giving the company a market cap of $32M. The stock is currently down 38.8% year-to-date, down 45.7% over the past 12 months, and down 56.1% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 1.2%. Trading Activity Trading volume this week was 9.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 166.7% The company's stock price performance over the past 12 months lags the peer average by 208.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Reasons You should Get this: FuelCell Energy, Inc. (NASDAQ:FCEL -7.88%), Alterity Therapeutics Limited (NASDAQ:ATHE -1.06%) appeared first on Stocks Equity .

In last trading session, Alterity Therapeutics Limited (NASDAQ:ATHE) saw 0.3 million shares changing hands with its beta currently measuring 1.51. Companys recent per share price level of $0.86 trading at -$0.07 or -7.03% at ring of the bell on the day assigns it a market valuation of $39.23M. That closing price of ATHEs stock is Alterity Therapeutics Limited (NASDAQ:ATHE) 1.16% Above Its 52-Week Low, But Can It Keep Rising? Read More »

MELBOURNE, Australia and SAN FRANCISCO, Nov. 22, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing dise

MELBOURNE, Australia  and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing d

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

MELBOURNE, Australia, Aug. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treat

The stock price of Alterity Therapeutics Ltd (NASDAQ: ATHE) increased by over 15% pre-market. This is why it happened.

MELBOURNE, Australia, July 15, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying trea

The stock price of Alterity Therapeutics Ltd (NASDAQ: ATHE) fell by over 12% pre-market. These are the details.

Alterity Therapeutics Ltd (NASDAQ:ATHE) (ASX:ATH) surged 58% in pre-market trade in New York as the company announced the award of a new patent, which advances its journey towards finding a clinical c

The stock price of Alterity Therapeutics Ltd (NASDAQ: ATHE) increased by over 60% during intraday trading. This is why it happened.

MELBOURNE, Australia and SAN FRANCISCO , July 1, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the granting of a new composition

Highlights: Alterity receives positive guidance from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. Concurren